Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6119797 | Journal of Clinical Virology | 2015 | 4 Pages |
Abstract
Overall SVR12 was 63% and our results suggest that HIV/HCV coinfected patients with low HCV viral load (<800,000Â IU/mL) and undetectable HCV-RNA after 4 weeks of triple therapy with TVR or BOC-based regimen have a higher probability of treatment success.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
D. Salmon, F. Bani-Sadr, C. Gilbert, E. Rosenthal, M.A. Valantin, A. Simon, D. Neau, P. Morlat, M.A. Loko, L. Wittkop, F. Dabis, ANRS CO13HEPAVIH study group ANRS CO13HEPAVIH study group,